Document is current
Any future updates will be listed below
-
Authors
Shiratori, Souichi http://orcid.org/0000-0002-5528-7112
Sugita, Junichi
Fuji, Shigeo
Aoki, Jun http://orcid.org/0000-0002-3412-0073
Sawa, Masashi
Ozawa, Yukiyasu
Hashimoto, Daigo
Matsuoka, Ken-ichi http://orcid.org/0000-0001-7955-8266
Imada, Kazunori
Doki, Noriko
Ashida, Takashi
Ueda, Yasunori
Tanaka, Masatsugu
Sawayama, Yasushi
Ichinohe, Tatsuo http://orcid.org/0000-0002-0393-4066
Terakura, Seitaro http://orcid.org/0000-0002-1194-8046
Morishima, Satoko http://orcid.org/0000-0002-7391-4271
Atsuta, Yoshiko http://orcid.org/0000-0003-4404-2870
Fukuda, Takahiro
Teshima, Takanori http://orcid.org/0000-0002-0941-271X
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (20ek0510025h0003)
- License Information
-
More Information
Article History
Received: 19 January 2021
Revised: 26 March 2021
Accepted: 13 April 2021
First Online: 7 May 2021
Compliance with ethical standards
:
: SF reports grants and personal fees from CSL Behring, outside the submitted work. MS reports personal fees from Chugai, Pfizer, Astellas, Nippon-Shinyaku, Ono, MSD, Bristol-Myers Squibb, Kyowa-Hakko Kirin, Asahi-Kasei, Novartis, Eisai, Otsuka, Sumitomo Dainippon, Sanofi, Takeda, Celgene, Mochida, Shire, Mundipharma, outside the submitted work. KM reports personal fees from Kyowa Kirin Co. Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Novartis Pharma Inc., Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd., MSD K.K., JIMRO Co. Ltd., outside the submitted work. KI reports personal fees from Chugai Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Novartis Pharma K.K., Celgene Co. Ltd., Bristol-Myers Squibb K.K., Takeda Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Otuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., outside the submitted work. TI reports other from Astellas Pharma, Chugai Pharmaceutical Co., CSL Behring, Eisai Co., FUJIFILM Wako Chemicals., Kyowa Kirin Co., Ono Pharmaceutical Co., Pfizer, Nippon Shinyaku Co., MSD, Otsuka Pharmaceutical Co., Repertoire Genesis Inc., Sumitomo Dainippon Pharma Co., Taiho Pharmaceutical Co., other from Takara Bio Inc., Takeda Pharmaceutical Co., Zenyaku Kogyo Co., personal fees from Bristol-Myers Squibb, Celgene, personal fees from Janssen Pharmaceutical K.K., Kyowa Kirin Co., outside the submitted work. ST reports personal fees from Chugai Pharmaceutical Co. Ltd., Yakult Honsha Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma, Astellas Pharma Inc., Novartis, Amgen Astellas BioPharma K. K., outside the submitted work. YA reports grants from AMED, during the conduct of the study; other from Astellas Pharma Inc., Mochida Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd, outside the submitted work. TT reports personal fees from Merck Sharp & Dohme, grants and personal fees from Kyowa Kirin, personal fees from Takeda, grants, personal fees, and non-financial support from Novartis, personal fees from Pfizer, Bristol-Myers Squibb, grants from Chugai, Sanofi, Astellas, Teijin Pharma, Fuji Pharma, Nippon Shinyaku, non-financial support from Janssen, grants from Japan Society for the Promotion of Science KAKENHI (17H04206), The Center of Innovation Program from Japan Science and Technology Agency, during the conduct of the study.
